Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Sana Biotechnology Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
SANA
Nasdaq
8731
https://sana.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Sana Biotechnology Inc
Director Patrick Yang Sells 25,000 Shares of Sana Biotechnology Inc (SANA)
- Mar 11th, 2024 11:00 pm
Baillie Gifford Bolsters Stake in Sana Biotechnology Inc
- Mar 7th, 2024 2:01 pm
Sana Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
- Feb 29th, 2024 9:05 pm
14 Stocks With Heavy Insider Buying In 2024
- Feb 29th, 2024 8:02 am
Sana Biotechnology to Present at the Cowen 44th Annual Health Care Conference
- Feb 28th, 2024 9:05 pm
Institutional investors are Sana Biotechnology, Inc.'s (NASDAQ:SANA) biggest bettors and were rewarded after last week's US$521m market cap gain
- Feb 19th, 2024 10:52 am
Sana Biotechnology Announces Publication of Preclinical Diabetes Data in Cell Stem Cell Demonstrating Insulin Independence Following Transplantation of Hypoimmune Allogeneic Primary Islet Cells Without Immunosuppression in a Diabetic NHP
- Feb 13th, 2024 9:05 pm
Sana Biotechnology Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
- Feb 12th, 2024 9:05 pm
Sana Biotechnology Announces Pricing of Upsized Public Offering
- Feb 8th, 2024 6:22 am
Sana Biotechnology Announces Proposed Public Offering of Common Stock
- Feb 7th, 2024 9:01 pm
Are You Looking for a Top Momentum Pick? Why Sana Biotechnology (SANA) is a Great Choice
- Jan 18th, 2024 5:00 pm
Sana Bio (SANA) Stock Rallies 105% in 3 Months: Here's Why
- Jan 18th, 2024 3:24 pm
Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC262, a Hypoimmune-modified, CD22-directed Allogeneic CAR T Therapy, for Patients with Relapsed or Refractory B-cell Malignancies
- Jan 5th, 2024 2:00 pm
Sana Biotechnology to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- Jan 3rd, 2024 9:05 pm
EVP Christian Hordo Sells 75,000 Shares of Sana Biotechnology Inc (SANA)
- Dec 19th, 2023 2:01 pm
Sana Biotechnology Highlights Preclinical Data Supporting Tumor Control and Immune Evasion Capabilities of Hypoimmune-Modified Allogeneic CAR T Cells in Presentations at the American Society of Hematology Annual Meeting
- Dec 11th, 2023 2:00 pm
Sana Biotechnology Publishes Early Clinical Data Showing that SC291, a CD19-directed Allogeneic CAR T Therapy, Evades Immune Detection in Presence of Intact Immune System
- Dec 1st, 2023 9:05 pm
Sana Biotechnology to Present at November and December 2023 Investor Conferences
- Nov 21st, 2023 2:00 pm
Flagship Pioneering Unveils Quotient Therapeutics to Create Transformative Medicines Informed by a New Frontier of Genetics
- Nov 21st, 2023 11:00 am
Uppsala University Hospital and Sana Biotechnology Announce Authorization of the First-in-Human Clinical Trial Application for a Primary Islet Cell Treatment for Patients with Type 1 Diabetes
- Nov 17th, 2023 2:00 pm
Scroll